Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.9104
Revised: October 8, 2013
Accepted: November 2, 2013
Published online: December 21, 2013
Core tip:131I-metuximab has high affinity with a target antigen highly expressed on hepatocellular carcinoma (HCC) cells and a limited area of action. The combination of metuximab and transcatheter arterial chemoembolization had a synergistic effect in the treatment of HCC. It may represent a promising treatment modality for patients with advanced HCC, especially for those patients with multiple nodules who have a heavy tumor burden.